Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.74 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.74 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.74 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.74 |
| ▸ | GAPDH | P04406 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | STAT6 | P42226 | 1/20 | 0.74 |
| ▸ | PI4KA | P42356 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.74 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.74 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.74 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926827 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15338536 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15338502 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL29936504 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15788449 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL41361 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL4666841 | 0.91 | ADORA1 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL24371423 | 0.91 | ADORA3 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL3447141 | 0.91 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL4581742 | 0.90 | P2RY1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | claimed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | claimed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | claimed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | claimed |
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | claimed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | claimed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | claimed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | claimed |
| CN-116381072-A | Biomarker for identifying sporadic gout and frequent gout and application thereof | 青岛大学附属医院 | 2023-07-04 | — | — | CN | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHONGQING UPGRA BIOLOGICAL SCI. & TECH., LTD. (CN) | 2020-08-20 | — | — | US | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8946188-B2 | Anti-microbial agents and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-02-03 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| WO-1996033703-A2 | S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY | ORIDIGM CORPORATION (US) | 1996-10-31 | — | — | WO | disclosed |
| EP-0720482-A1 | PROSAPOSIN AND CYTOKINE-DERIVED PEPTIDES AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995003821-A1 | PROSAPOSIN AND CYTOKINE-DERIVED PEPTIDES AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0601322-A2 | Adenosindeaminase inhibitor | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0269574-B1 | NOVEL ADENOSINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS AN ACTIVE INGREDIENT | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4843066-A | HYPOTENSIVE AGENTS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | ADORA1 28/4885SMN1; SMN2 3133/4885ADORA3 30/4885 |
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, SLC11A2 | ADORA1 3708/4885SMN1; SMN2 4713/4885ADORA3 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.